[A Case of Long-Term Complete Remission by Pembrolizumab+Axitinib, Cabozantinib for Papillary Renal Cell Carcinoma with Metastasis].

Q4 Medicine
Naoya Nakatake, Yushi Miyata, Tomohiro Kanaki, Takanori Kinjo, Wataru Nakata, Hitoshi Inoue
{"title":"[A Case of Long-Term Complete Remission by Pembrolizumab+Axitinib, Cabozantinib for Papillary Renal Cell Carcinoma with Metastasis].","authors":"Naoya Nakatake, Yushi Miyata, Tomohiro Kanaki, Takanori Kinjo, Wataru Nakata, Hitoshi Inoue","doi":"10.14989/ActaUrolJap_71_9_289","DOIUrl":null,"url":null,"abstract":"<p><p>A 46-year-old woman presented to a local clinic complaining of discomfort in the right upper quadrant. Abdominal ultrasound revealed a right renal mass, and she was referred for further evaluation and treatment. Contrast-enhanced computed tomography showed a 54 mm right renal tumor and a 12 mm enlarged lymph node in the aortocaval region. She was diagnosed with right renal cell carcinoma, staged as cT1bN1M0. Laparoscopic right nephrectomy and lymph node dissection were performed, confirming the diagnosis of papillary renal cell carcinoma type 2, pT1bpN1. At nine months after surgery, she developed retroperitoneal recurrence with invasion of the second lumbar vertebra. Pembrolizumab combined with axitinib was initiated. After six months of treatment, she achieved a complete response with no detectable lesions. However, 17 months after the initiation of treatment, new multiple liver metastases appeared, and the response was classified as progressive disease. Second-line treatment with cabozantinib was started, leading to complete tumor regression after 16 months, with a complete response confirmed. She has maintained a complete response for 39 months since starting cabozantinib.</p>","PeriodicalId":39291,"journal":{"name":"Acta Urologica Japonica","volume":"71 9","pages":"289-293"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Urologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14989/ActaUrolJap_71_9_289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

A 46-year-old woman presented to a local clinic complaining of discomfort in the right upper quadrant. Abdominal ultrasound revealed a right renal mass, and she was referred for further evaluation and treatment. Contrast-enhanced computed tomography showed a 54 mm right renal tumor and a 12 mm enlarged lymph node in the aortocaval region. She was diagnosed with right renal cell carcinoma, staged as cT1bN1M0. Laparoscopic right nephrectomy and lymph node dissection were performed, confirming the diagnosis of papillary renal cell carcinoma type 2, pT1bpN1. At nine months after surgery, she developed retroperitoneal recurrence with invasion of the second lumbar vertebra. Pembrolizumab combined with axitinib was initiated. After six months of treatment, she achieved a complete response with no detectable lesions. However, 17 months after the initiation of treatment, new multiple liver metastases appeared, and the response was classified as progressive disease. Second-line treatment with cabozantinib was started, leading to complete tumor regression after 16 months, with a complete response confirmed. She has maintained a complete response for 39 months since starting cabozantinib.

【派姆单抗+阿西替尼、卡博赞替尼治疗转移性乳头状肾细胞癌长期完全缓解1例】。
一名46岁妇女到当地一家诊所就诊,主诉右上腹部不适。腹部超声显示右肾肿块,她被转介进一步评估和治疗。增强计算机断层扫描显示一个54毫米的右肾肿瘤和主动脉下腔区一个12毫米的肿大淋巴结。诊断为右肾细胞癌,分期为cT1bN1M0。行腹腔镜右肾切除术及淋巴结清扫,确诊为2型乳头状肾细胞癌,pT1bpN1。手术后9个月,她出现腹膜后复发并侵犯第二腰椎。Pembrolizumab联合阿西替尼开始。经过六个月的治疗,她获得了完全的缓解,没有可检测到的病变。然而,在开始治疗17个月后,出现了新的多发性肝转移,反应被归类为进展性疾病。开始卡博赞替尼二线治疗,16个月后肿瘤完全消退,证实完全缓解。自开始使用卡博赞替尼以来,她保持了39个月的完全缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Urologica Japonica
Acta Urologica Japonica Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
74
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书